J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
chemotherapy
Advertisement
Lilly’s Taltz and Zepbound Show One-Year Benefits
Indianapolis, Indiana, August 31, 2026 Eli Lilly and Company announced new Phase 3b data showing that treatment with Taltz®...
Jazz Reports Survival Benefit for Ziihera in GEA
Dublin, Ireland, August 31, 2026 Jazz Pharmaceuticals plc announced positive topline results from the Phase 3 HERIZON-GEA-01 clinical trial,...
Can-Fite BioPharma Reports Namodenoson Pancreatic Cancer Findings
Ramat Gan, Israel — August 17, 2026 Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhanced the...
Mendaera Reports 98% Success for Focalist System
San Mateo, California, August 12, 2026 Mendaera Inc. announced results from a new peer-reviewed prospective multispecialty study showing that...
Advertisements
Freenome Gains FDA Breakthrough Device Designation
Brisbane, California, August 12, 2026 Freenome, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Taiho Oncology Advances Zipalertinib in Phase 3 Trial
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
Amplia Therapeutics Reports Promising Preclinical Narmafotinib Data in Pancreatic Cancer
MELBOURNE, Australia, July 30, 2026 Amplia Therapeutics announced the online publication of comprehensive preclinical findings evaluating narmafotinib in pancreatic...
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
Revolution Medicines Reports Promising Phase 1/2 Zoldonrasib Combination Data in Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...
Advertisement
